Avedro Inc (NASDAQ:AVDR) saw a large drop in short interest in June. As of June 30th, there was short interest totalling 215,800 shares, a drop of 15.6% from the May 30th total of 255,800 shares. Currently, 1.9% of the shares of the company are sold short. Based on an average daily volume of 112,600 shares, the short-interest ratio is currently 1.9 days.

AVDR stock traded down $0.29 during trading on Friday, reaching $19.69. The company had a trading volume of 56,410 shares, compared to its average volume of 134,925. The business has a 50-day simple moving average of $19.40. The company has a quick ratio of 9.09, a current ratio of 9.60 and a debt-to-equity ratio of 0.36. Avedro has a twelve month low of $10.75 and a twelve month high of $22.52.

Avedro (NASDAQ:AVDR) last released its earnings results on Thursday, May 9th. The company reported ($1.00) EPS for the quarter, topping analysts’ consensus estimates of ($1.01) by $0.01. The company had revenue of $8.77 million during the quarter, compared to analyst estimates of $7.93 million. On average, equities research analysts expect that Avedro will post -2.25 earnings per share for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Catalyst Capital Advisors LLC purchased a new position in Avedro during the 1st quarter worth approximately $31,000. FNY Investment Advisers LLC purchased a new position in Avedro during the 1st quarter worth approximately $91,000. Spark Investment Management LLC purchased a new position in Avedro during the 1st quarter worth approximately $192,000. Gilder Gagnon Howe & Co. LLC purchased a new position in Avedro during the 1st quarter worth approximately $209,000. Finally, Falcon Point Capital LLC purchased a new position in Avedro during the 1st quarter worth approximately $261,000. 60.38% of the stock is owned by institutional investors.

Avedro Company Profile

Avedro, Inc, an ophthalmic pharmaceutical and medical device company, develops and commercializes products to treat ophthalmic disorders and conditions, primarily associated with corneal weakness. The company's Avedro Corneal Remodeling platform comprises KXL and Mosaic systems, which deliver ultraviolet A or UVA light, and a suite of single-use riboflavin drug formulations.

Read More: Liquidity

Receive News & Ratings for Avedro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avedro and related companies with MarketBeat.com's FREE daily email newsletter.